The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial.
M. Karthaus
Honoraria - Lilly
Other Remuneration - Lilly
I. Poddubnaya
No relevant relationships to disclose
L. Churilova
No relevant relationships to disclose
R. Khasanov
No relevant relationships to disclose
T. Veremeychuk
No relevant relationships to disclose
E. Rumyantseva
No relevant relationships to disclose
M. Garin
No relevant relationships to disclose
O. Brichkova
No relevant relationships to disclose
B. Heinrich
Research Funding - Lilly
V. Heinemann
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Research Funding - Lilly
Other Remuneration - Lilly